New Key Statistics Module, Z-Score and F-Score
NAS:DERM Key Ratios
| Market Cap $ M | 208.30 |
| Enterprise Value $ M | 208.19 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | 10.88 |
| Price/Book | 6.36 |
| Price/Sales | 2.90 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 68.00 |
| EPS (TTM) $ | -0.22 |
| Beneish M-Score | -1.42 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -- |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -85.99 |
| EV-to-EBITDA | 109.92 |
| PEG | -- |
| Shares Outstanding M | 28.22 |
| Net Margin (%) | -8.95 |
| Operating Margin % | -4.41 |
| Pre-tax Margin (%) | -8.93 |
| Quick Ratio | 1.41 |
| Current Ratio | 1.59 |
| ROA % (ttm) | -6.77 |
| ROE % (ttm) | -21.81 |
| ROIC % (ttm) | -7.61 |
| Dividend Yield % | -- |
| Altman Z-Score | 1.36 |
DERM Number of Guru Trades
DERM Volume of Guru Trades
Gurus Latest Trades with NAS:DERM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:DERM is held by these investors
Total 1
Journey Medical Corp Insider Transactions
No Available Data
Guru Commentaries on NAS:DERM
Summers Value Fund
Bullish
2025 Q3
What the manager wrote
Journey Medical develops and markets dermatology products, recently launching Emrosi for the treatment of rosacea. The rollout is on track, with annualized sales approaching $30 million in the first six months. We believe Emrosi could exceed $100 million in peak sales based on positive physician and patient feedback. The company is positioned for profitability in 2026, supported by a scalable business model. Given ongoing consolidation in the dermatology industry, Journey may also be viewed as an attractive acquisition candidate.
News about NAS:DERM
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers